Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Cancer vaccine MUC-1 (Primary) ; Poly ICLC (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 19 Jun 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Aug 2015, as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 02 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.